Singapore’s CBC Group, an Asian healthcare asset management firm, has completed the acquisition of global biopharmaceutical company UCB's mature neurology and allergy business in China, in partnership with Mubadala Investment Company, an Abu Dhabi global investment firm.
The $680 million deal includes UCB's brands Keppra, Vimpat, Neupro, Zyrtec, Xyzal, and the Zhuhai manufacturing site, according to a media release.
The acquisition continues Singapore-headquartered CBC's strategy of acquiring assets from global pharmaceutical companies and in building a neurology company in China while expanding CBC’s portfolio within the region's pharmaceutical market.
The medicine portfolio will become “an anchor asset” as CBC builds...
¬ Haymarket Media Limited. All rights reserved.
